XRAY (DENTSPLY SIRONA Inc.) Stock Analysis - Financials

DENTSPLY SIRONA Inc. (XRAY) is a publicly traded Healthcare sector company. As of May 21, 2026, XRAY trades at $9.99 with a market cap of $1.97B and a P/E ratio of 1.92. XRAY moved +1.03% today. Year to date, XRAY is -15.25%; over the trailing twelve months it is -41.11%. Its 52-week range spans $9.41 to $27.44. Analyst consensus is neutral with an average price target of $13.88. Rallies surfaces XRAY's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are XRAY's key financials?

XRAY financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. XRAY recently traded at $9.99. Market cap is $1.97B. P/E ratio is 1.92. Revenue is $24.78B.

XRAY Key Metrics

Key financial metrics for XRAY
MetricValue
Price$9.99
Market Cap$1.97B
P/E Ratio1.92
EPS$5.19
Dividend Yield0.16%
52-Week High$27.44
52-Week Low$9.41
Volume0
Avg Volume0
Revenue (TTM)$24.78B
Net Income$3.69B
Gross Margin58.94%

XRAY Annual Financials

YearRevenueNet IncomeEPS
2025$3.68B$-598.00M$-3.00
2024$3.79B$-910.00M$-4.48
2023$3.96B$-132.00M$-0.62
2022$3.92B$-950.00M$-4.41

Latest XRAY News

Recent XRAY Insider Trades

  • LUCIER GREGORY T bought 15.00K (~$186.68K) on Mar 9, 2026.
  • Forbes James D bought 5.00K (~$62.40K) on Mar 9, 2026.
  • LUCIER GREGORY T bought 22.45K (~$314.86K) on Mar 3, 2026.

XRAY Analyst Consensus

14 analysts cover XRAY: 0 strong buy, 3 buy, 9 hold, 2 sell, 0 strong sell. Consensus rating is neutral. Average price target: $13.88.

Common questions about XRAY

What are XRAY's key financials?
XRAY financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. XRAY recently traded at $9.99. Market cap is $1.97B. P/E ratio is 1.92. Revenue is $24.78B.
Is XRAY research on Rallies investment advice?
No. Rallies provides research, data, and educational context for XRAY. It does not provide personalized investment advice.
XRAY

XRAY